AbCellera Biologics Up; Expands Agreement With Gilead
01 Aprile 2021 - 4:37PM
Dow Jones News
By Michael Dabaie
AbCellera Biologics Inc. shares were up 8.5%, to $36.84, in
Thursday morning trading.
AbCellera said before the market open that it would expand its
collaboration with Gilead Sciences Inc., including a multi-year,
multi-target antibody-discovery collaboration and access to
AbCellera's humanized mouse technology, the Trianni Mouse.
AbCellera will receive an upfront payment and is eligible for
milestone payments and royalties based on the development and
commercialization of antibodies generated by AbCellera under this
collaboration.
Under the new agreement, AbCellera will generate panels of
antibodies for up to eight new targets, across multiple
indications, selected by Gilead.
Gilead shares were up 1.5%, to $65.60.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 01, 2021 10:22 ET (14:22 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Lug 2023 a Lug 2024